Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight...
Drug Administration Ligand Pharmaceuticals Incorporated Therapeutics Inc Study Achieves Primary Secondary Endpoints Body Weight
Source: marketscreener.com